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INTRODUCTION 
 
Patients with advanced Parkinson’s disease experience motor fluctuations that seem to 
be related with variations in their serum levels of L-dopa and dopaminergic agonists. 
Therefore, drug infusion pumps have been developed with the aim of maintaining stable 
serum levels and reducing motor fluctuations [1]. Such pumps are usually programmed 
with a constant infusion rate. Some pumps also allow the patient to self-administer a 
rescue dose when necessary. Adjusting the schedule for a patient often requires several 
visits to the physician or admissions to hospital, especially at the beginning of the 
treatment [2].  
 
Information and communication technologies make it possible to control infusion 
pumps remotely, thus reducing the number of necessary visits to the physician and/or 
improving the control of the disease. Furthermore, the technological development of 
sensors allows for the design of smaller and more wearable systems to detect motor 
fluctuations [3]. Such sensors can automatically detect the moments in which a patient 
needs more doses [4], thus allowing for automatic or semi-automatic control of the 
infusion pump. Consequently, the infusion rate might be adjusted to the unpredictable 
motor fluctuations of some patients in real time.  
 
During the course of the HELP project, a technological system for remote real-time 
control of apomorphine pumps was developed [5]. The system includes a kinematic 
sensor able to detect motor symptoms and send the information through a mobile phone 
(gateway) to a central server. In the server, the symptoms can be analyzed by an expert, 
who readjusts the apomorphine dose accordingly with the detected motor phase (ON or 
OFF). The new dose is sent back through the mobile-gateway to the wireless pump. 
 
 In this article, we report the results of a proof of concept, where real-time dose 
variations were introduced according to the patient’s motor state. Although the HELP 
system includes an inertial sensor that can detect the patient’s motor state, in this proof 
of concept, dose decisions were not based on the readings from the sensor (in process of 
validation) but on the motor state the patients reported by telephone. 
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METHOD 
 
Quasi-experimental study conducted on a group of 6 patients, with a before-after design 
(pre-post intervention). All patients included suffered from idiopathic Parkinson’s 
disease, according to the criteria of the Brain Bank of London [6]; they experienced 
motor fluctuations and used apomorphine pumps. Patients with severe dyskinesia or 
dystonia, severe orthostatic hypotension, risk of Torsades-de-Pointes arrhythmia, 
anaemia, liver or kidney failure and those wearing other implantable electronic devices 
were excluded. Participants were selected by convenience sampling in 4 hospitals. The 
field work was conducted in Madrid and Barcelona (Spain) between October 2012 and 
March 2013. 
  
Participants – who were already users of apomorphine pump – used the HELP infusion 
pump programmed to a constant rate corresponding to the patient’s habitual dose, for 5-
6 days (pre-intervention phase). Subsequently, they used the same pump for 5-6 days, 
though with remotely controlled variations in the infusion rate depending on their motor 
state (post-intervention phase). The change-of-dose protocol involved using the 
patients’ habitual doses when they were in the On state and 25% or 50% higher rates 
(depending on their tolerance as evaluated in pre-test trials) when they entered the Off 
phase and until they returned to the On phase (when previous basal rate was set again). 
New doses were set in the pump from a remote position, using the specific software and 
communications of the HELP system. Patients could report changes in their motor 
activity by calling at any time a medical operator, who was in charge of re-adjusting the 
dose. The medical operator also called the patients every two hours. 
 
The main study variable was the time patients spent in either of the states (On, Off or a 
“intermediate” phase between both) during the continuous infusion period (pre-
intervention phase) and the remotely controlled infusion period (post-intervention 
phase). Patients were asked to record their motor state every 30 minutes on a specially 
designed paper calendar. The medical operator who was in charge of calling them by 
telephone every 2 hours also recorded the patients’ motor state, thus supplementing the 
data recorded by patients. For patients using apomorphine rescue, the number of 
injections, dose and time were recorded. No further modifications were allowed in 
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dopaminergic medication during the time of the study. Adverse effects occurred during 
the experimental time were systematically recorded. 
 
Descriptive statistical analysis was performed for each patient; the total time a patient 
spent in either of the three above defined motor states was computed. For patients using 
rescue injections, the number of injections they needed during the time of the study was 
recorded. The analysis compared all the “post-intervention” time, where apomorphine 
doses were remotely controlled (6 daily hours minimum), against an equivalent period 
of the “pre-intervention” phase (same times of the day), where apomorphine doses 
remained stable at patient’s usual rate. Once a patient was included in the analysis, 
occasions where the dose-change protocol could not be completed due to technical 
failure were not excluded from the analysis (to avoid a selection bias of ON episodes). 
Differences in the time-in-Off and the number of necessary apomorphine rescues 
between the pre- and the post-intervention phases were analyzed by using the Wilcoxon 
test. Reported adverse effects were recorded. 
 
The study protocol was approved by the Consorci Sanitari del Maresma Ethical 
Committee. All participants provided informed consent prior to their inclussion in the 
study.   
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RESULTS 
 
Only 3 participants out of the 6 initially enrolled ones were included in the analysis. 
Two patients were excluded due to coverage problems that affected remote control of 
the pump through the HELP system, and one patient was excluded because the remote 
control system broke down. 
 
Table 1 shows the general characteristics, baseline and increased apomorphine doses 
and number of days in the study corresponding to every participant patient.  
 
For participants 4 and 6, who did not use apomorphine rescues, the time in On was 
slightly longer (7.1%, p=0.17) and the time in Off was 10% shorter (p < 0.05) in the 
post-intervention phase. Patient 2 used apomorphine rescues during both pre and post-
intervention phases. Therefore the results in terms of  On/Off times were confusing; 
during the experimental time this patient spent longer times in the On and Off states, 
and consequently shorter time in the intermediate state, as compared with the first week. 
However, this patient needed a mean of 4 apomorphine rescues per day during the pre-
intervention phase and 3 rescues per day during the post-intervention period (one third 
of the latter rescues were administered out of experimental hours). Table 2 shows the 
results corresponding to these three patients. 
 
Regarding adverse side effects, three cases of low blood pressure were recorded, two of 
them during the pre-intervention period. The three cases were self-limited and no 
intervention was required. One of the patients experienced excessive somnolence during 
the post-intervention period, which could be related with variations in the apomorphine 
infusion rate. No further adverse side effects with a possible relationship with the 
treatment were recorded.  
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DISCUSSION 
 
The present study is a proof of concept, designed to test remote control of apomorphine 
infusion pumps. Furthermore, the possible effects on the patient of an intensive real-
time dose adjustment that depends on the patient’s motor state, have been explored. As 
far as we know this is the first time that either of these challenges are attempted. 
 
Remote control of the apomorphine pump was acceptable for 3 out of 6 patients, which 
demonstrates that such monitoring method is technically feasible. However, the fact that 
the HELP system depends on the mobile phone network prevents its use in Spain, where 
many geographical locations have a deficient mobile data broadband coverage. Remote 
control could potentially facilitate initial and long-term dose adjustment, thus reducing 
the number of admissions to hospital and visits to the physician needed for dose 
adjustment, especially during the initial phases of treatment [2].  
 
Intensive adjustment of the apomorphine dose, in response to patients’ motor 
fluctuations, could be done either manually by the patient or automatically through the 
use of new technologies for detection of motor symptoms [3]. This study is a proof of 
concept which, despite limited results due to the small sample size, shows a tendency 
towards an improved symptom control (shorter time in Off; less rescues needed) during 
the intervention periods, where the dose was changed depending on the patient’s motor 
state. These results support the need for further studies aimed at exploring the possible 
benefits of this alternative dosing method. 
 
Although this study is only an initial proof of concept, we postulate that “intelligent” 
devices that detect the patient’s motor state and act accordingly, are feasible and 
constitute a line of research with a great potential for the future. The increasing 
development of mobile data broadband in our country will facilitate the use of such 
tools for telemedicine projects like the present one.  
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